ROCO
4127
Market cap45mUSD
Nov 12, Last price
30.80TWD
Name
Tien Liang Biotech Co Ltd
Chart & Performance
P/E
120.50
P/S
3.66
EPS
0.26
Div Yield, %
1.62%
Shrs. gr., 5y
—
Rev. gr., 5y
-12.31%
Revenues
385m
-16.26%
Net income
12m
-34.04%
CFO
48m
-30.62%
Dividend
Aug 27, 20240.5 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese medicine products, such as pills for liver and kidney deficiency, low back pain, sore feet, dizziness, thirst, dry tongue, sore throat, and heel pain, as well as rheumatism, joint pain, traveling pain, wind-cold-dampness, gout, neuralgia, enuresis, hemorrhoids, constipation, athlete's foot, fall injuries, cold, bronchitis, cough, and phlegm indications. It provides western medicine products, including ointment, hair removal cream, tablet, capsule, soreness spray, and pain patch products, as well as pain relief gels. In addition, the company offers healthcare products; and other products for body relaxation and comfort, and relieving discomfort after exercise, as well as tooth products and soaps. The company was founded in 1960 and is based in New Taipei City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||